Articles related to HEALTHCARE COSTS

Discover how a recent class-action lawsuit against Bristol Myers Squibb could impact the availability and cost of multiple myeloma treatment options.

Discover how the 340B Drug Pricing Program influences prescription trends toward higher-cost biologics over biosimilars, and what this means for cost-effective healthcare.

New research underscores the dramatic increase in prior authorization for oral oncology drugs under Medicare Part D. Understand the implications for your practice as insurers tighten their grip on treatment decisions.

The HHS has initiated a landmark policy to negotiate drug prices under Medicare Part D. Be prepared for how these changes could affect your patients’ medication affordability starting in 2026.

The SAGE-AF study provides valuable insights into the cost-reducing behaviors among older adults with atrial fibrillation, highlighting the need for targeted interventions, especially for those with cognitive impairments. Explore the study to understand how these behaviors are shaping medication management in this vulnerable population.

The recent study exploring the Mark Cuban Cost Plus Drug Company’s potential impact on Medicare’s oncology drug spending uncovers significant savings opportunities. Physicians may find interest in this model’s potential to improve access to essential cancer medications through reduced costs, emphasizing a call to examine current overpayment within the Medicare system.